Regulatory & Compliance

A federal policy designed to overhaul a critical drug pricing program for the nation's most vulnerable hospitals was dismantled not by political debate or public outcry, but by a precise legal maneuver that halted its implementation just days before it was set to begin. The swift and total collapse

With the recent launch of the TrumpRx portal, the White House has waded directly into the complex world of pharmaceutical sales, promising lower prices for Americans. To unpack the real-world implications of this move, we're speaking with James Maitland, a leading analyst whose work has

In a significant challenge to the long-criticized practices that drive up prescription drug costs in the United States, the Federal Trade Commission (FTC) has finalized a landmark settlement with Express Scripts, one of the nation’s most powerful pharmacy benefit managers (PBMs). This agreement

A Looming Crisis: Why a New Rate Proposal Has Shaken the Medicare Advantage Landscape For years, Medicare Advantage (MA) has been a cornerstone of American senior healthcare, growing exponentially as a popular private alternative to traditional Medicare. However, the program's seemingly unstoppable

In a surprising display of resilience, the U.S. Food and Drug Administration’s Center for Devices and Radiological Health (CDRH) not only maintained its operational tempo but also increased its authorization of novel medical devices in 2025, a period marked by significant staff reductions under the

A Federal Reckoning: Targeting the Middlemen of Medicine The persistent and escalating cost of prescription drugs in the United States has ignited widespread public frustration and become a recurring battleground in political debate. A proposed rule from the Department of Labor (DOL) is now taking